Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer

Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as Second Line Therapy in Patients With Stage IIIB or Stage IV Non Small Cell Lung Cancer (NSCLC)

Phase 2 study to investigate the efficacy and tolerability of epothilone ZK 219477 in patients with stage IIIb or stage IV non-small-cell lung cancer.

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Inclusion Criteria:

• Non-small-cell lung cancer
• Only one previous chemotherapy with a platinum-containing drug
• Use of highly effective birth control methods in females of child-bearing potential

Exclusion Criteria:

• No more than 1 previous chemotherapy for advanced disease
• Previous participation in another trial within the last 4 weeks
• Breast feeding
• Active infections